Insider Selling: Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Major Shareholder Sells 34,101 Shares of Stock

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) major shareholder Opaleye Management Inc. sold 34,101 shares of the stock in a transaction on Monday, October 11th. The stock was sold at an average price of $5.01, for a total value of $170,846.01. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Opaleye Management Inc. also recently made the following trade(s):

  • On Friday, October 8th, Opaleye Management Inc. sold 43,692 shares of Eton Pharmaceuticals stock. The stock was sold at an average price of $5.00, for a total value of $218,460.00.
  • On Friday, August 6th, Opaleye Management Inc. sold 345,000 shares of Eton Pharmaceuticals stock. The stock was sold at an average price of $5.84, for a total value of $2,014,800.00.
  • On Wednesday, August 4th, Opaleye Management Inc. sold 104,000 shares of Eton Pharmaceuticals stock. The stock was sold at an average price of $5.75, for a total value of $598,000.00.

Shares of NASDAQ ETON opened at $5.43 on Thursday. Eton Pharmaceuticals, Inc. has a 52 week low of $4.03 and a 52 week high of $10.30. The business has a 50-day simple moving average of $4.95 and a two-hundred day simple moving average of $6.23. The company has a debt-to-equity ratio of 0.29, a quick ratio of 8.96 and a current ratio of 9.36.

Eton Pharmaceuticals (NASDAQ:ETON) last issued its quarterly earnings results on Sunday, August 15th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.14) by $0.04. The business had revenue of $3.07 million for the quarter, compared to the consensus estimate of $3.83 million. On average, equities research analysts expect that Eton Pharmaceuticals, Inc. will post 0.34 EPS for the current fiscal year.

ETON has been the subject of several research reports. B. Riley reiterated a “buy” rating on shares of Eton Pharmaceuticals in a research note on Monday, August 16th. HC Wainwright restated a “buy” rating and issued a $14.00 target price on shares of Eton Pharmaceuticals in a research note on Tuesday, September 7th. Finally, TheStreet downgraded Eton Pharmaceuticals from a “c-” rating to a “d+” rating in a research note on Monday, August 9th.

Institutional investors and hedge funds have recently modified their holdings of the company. Advisory Services Network LLC bought a new stake in shares of Eton Pharmaceuticals during the 2nd quarter valued at about $25,000. Financial Advisors Network Inc. bought a new stake in shares of Eton Pharmaceuticals during the 2nd quarter valued at about $65,000. CHICAGO TRUST Co NA bought a new stake in shares of Eton Pharmaceuticals during the 3rd quarter valued at about $84,000. XTX Topco Ltd bought a new stake in shares of Eton Pharmaceuticals during the 2nd quarter valued at about $91,000. Finally, Barclays PLC boosted its position in shares of Eton Pharmaceuticals by 159.1% during the 1st quarter. Barclays PLC now owns 14,278 shares of the company’s stock valued at $104,000 after acquiring an additional 8,767 shares during the last quarter. Hedge funds and other institutional investors own 27.81% of the company’s stock.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc engages in the development, acquisition, and commercialization of prescription drug products. Its products include Biorphen, Alaway Preservative Free, zonisamide oral suspension, topiramate oral suspension, lamotrigine for oral suspension, cysteine injection, and ephedrine ready-to-use injection.

Further Reading: How dollar cost averaging works

Insider Buying and Selling by Quarter for Eton Pharmaceuticals (NASDAQ:ETON)

Receive News & Ratings for Eton Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eton Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.